Skip to main content
. 2022 Oct 19;10(10):2635. doi: 10.3390/biomedicines10102635

Figure 6.

Figure 6

Evolution of Sino-Nasal Outcome Test-22 (SNOT-22) score in a subgroup of 22 patients with co-existing severe refractory asthma and nasal polyposis, pre-treatment and after 52-week treatment with mepolizumab 100 mg every 4 weeks. Asterisks indicate statistical significance (**** p < 0.001).